Feb 23, 2022

Nurosene Announces A Change in Leadership

Welcome aboard! Your submission has been received and you are now a member of the MedicalGold.ca community.
Oops! Something went wrong while submitting the form. Please check the format of your entry.
Subscribe to Excellence

TORONTO, Feb. 23, 2022 /CNW/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF) today announced that Ranj Bath has stepped down as CEO to pursue other interests.

"I wish to personally thank Ranj for helping set the foundation for Nurosene since this journey began and we wish him our best in his future endeavours."
~ Kevin Taylor, Chairman of the Board

Furthermore, the Company is now announcing that George Achilleos will move into the position of CEO and President and will lead the Nurosene team and the execution of its strategic plan. George has been a key driver of the company's strategic planning process and has been involved since IPO, as a member of the Advisory Board.  He has held the position of COO and President, prior to this change.  Over his 25+ years of business, he has led over $50M of business deals / transactions / financings and his businesses have generated over $70M of cumulative revenue in the verticals of technology, e-commerce / digital marketing and nanotechnology.

"I am very excited about the future of Nurosene.  The strategic plan is in place and the Company is hitting milestones and making clear strides forward.  We have a great team that I look forward to working with, in the role of CEO."
~ George Achilleos, CEO
"George brings over 25 years of business executive and entrepreneurial experience to Nurosene, he has led multimillion dollar financings and deal flow in the areas of technology, e-commerce and nanotechnology and is an expert in early-stage company development."
~ Kevin Taylor, Chairman of the Board

About Nurosene

Nurosene is a healthtech company focused on delivering innovative AI based technology solutions that support mental performance and wellness. Our mission is to build healthier, more productive brains by leveraging our cutting-edge technology. Our world-renowned team and partners are disrupting traditional mental wellness treatments and are positioned at the forefront of critical research and innovations. NetraMark, a wholly owned subsidiary of Nurosene Health Inc., is providing proprietary next-generation AI solutions for pharmaceutical and biotechnology companies across the spectrum of disease.

For more information, visit www.nurosene.com.

Forward-Looking Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which is based upon Nurosene's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact.

Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Nurosene's Final Long Form Prospectus dated May 20, 2021 and Management's Discussion and Analysis for the year ended September 30, 2021 ("MD&A"),  and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in Nurosene's Final Long Form Prospectus and MD&A could cause actual events or results to differ materially from those described in any forward-looking information.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Nurosene Health Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2022/23/c5492.html

DISCLAIMER:

The work included in this article is based on current events, technical charts, company news releases, and the author’s opinions. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. This publication contains forward-looking statements, including but not limited to comments regarding predictions and projections. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. This publication is provided for informational and entertainment purposes only and is not a recommendation to buy or sell any security. Always thoroughly do your own due diligence and talk to a licensed investment adviser prior to making any investment decisions. Junior resource and biotechnology companies can easily lose 100% of their value so read company profiles on www.SEDARplus.ca for important risk disclosures. It’s your money and your responsibility.